Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:17:08 2026-05-21 am EDT			5-day change	1st Jan Change
289.12 ^DKK	+0.25%		+1.71%	-10.56%

12:19am	Bernstein raises price target for Novo Nordisk to DKK 200 (175), reiterates underperform - BN	FW
May. 20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE

Key obesity drug figure departs Novo Nordisk

Published on 04/09/2026 at 09:47 am EDT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+0.23%

Lotte Bjerre Knudsen, a pivotal figure behind the success of Novo Nordisk's GLP-1 therapies, is leaving the company after 36 years. The news was first reported by Bloomberg following a post on her LinkedIn profile.

Knudsen stated that her tenure at the firm is drawing to a close, though she provided no further details regarding the reason for her departure or her future plans.

Latest news about Novo Nordisk A/S

12:19am	Bernstein raises price target for Novo Nordisk to DKK 200 (175), reiterates underperform - BN	FW
May. 20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
May. 20	Blackrock Greater Europe reports "disappointing" return for first half	AN
May. 20	DNB Grønt Skifte Norden gains 8.47 percent in April - rotates from Boliden to Lundin Mining	FW
May. 20	NOVO NORDISK : Deutsche Bank sticks Neutral	ZD
May. 20	Intron: Novo Nordisk sales could decline in 2027	FW
May. 20	Medpal AI launches new health GLP-1 sub-brand	RE
May. 20	Nordic Equities in North America - Autoliv Gains 0.9 Percent	FW
May. 19	Can Nvidia Do It Again?
May. 19	Novo Nordisk highlights semaglutide for the treatment of silent liver disease	FW
May. 19	Novo Nordisk to present semaglutide data on liver disease	RE
May. 19	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
May. 19	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 19	The stock market still recoils at the prospect of higher rates
May. 19	Novo Nordisk Says 'Disappointed' by US Supreme Court Decision in Medicare Drug Pricing Case	MT

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company